Project Grant R01CA303989
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $500K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Farmington, CT 06030, USA
Similar Awards
- Federal Project Grant Award Summary Vivere Oncotherapies, Inc. received a $306,871 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on September 5, 2025, to support the clinical translation of OV-151, an evolved oncolytic virotherapy product designed to treat colorectal cancer. The grant funds a 12-month research period concluding August 31, 2026, focused on advancing this viral vector-based immunotherapeutic candidate through...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The University of Cincinnati received a $162,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2025, through June 30, 2027. This award funds research to develop and evaluate novel combination treatment strategies targeting colorectal cancer patients with KRAS mutations. The project specifically investigates the efficacy of combining KRAS inhibitors with HER3 (human epidermal...
- Federal Grant Award Summary The University of Virginia received a $192,888 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), effective September 1, 2025, through August 31, 2028. This award supports a novel research initiative designed to identify causal genetic variants associated with colorectal cancer (CRC) risk and elucidate their mechanistic effects through the use of normal colon organoids. The project addresses a critical gap in...
- Federal Grant Award Summary The University of Connecticut Health Center received a $414,585 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for the development and validation of a programmable enzyme-assisted mutation sequencing (PEAM-SEQ) diagnostic platform. The research, which commenced on May 6, 2026 and is scheduled for completion by April 30, 2029, focuses on developing noninvasive liquid biopsy technologies for...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $433,256 under the Cancer Treatment Research program (CFDA 93.395) for the period of September 1, 2025 through August 31, 2027. This award supports exploratory research into the role of antisense ribonucleic acids (asRNAs) in melanoma development and transformation. The project will deliver scientific research and analysis focused on...
- Federal Grant Award Summary The University of California, San Diego received a $671,226 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded May 15, 2026, with completion targeted for April 30, 2031. The project, "Colorectal Cancer Therapies Introduced Through Engineered Native Bacteria," will develop a microbial platform technology using engineered native E. coli strains derived from human gut bacteria to deliver...
- Federal Project Grant Award Summary The National Cancer Institute awarded $730,398 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, with a completion date of March 31, 2031. This project grant supports research into the emergence of tumor regenerative states during neoadjuvant therapy in locally advanced rectal cancer (LARC). The research aims to determine whether resistance to total neoadjuvant therapy (TNT)—which...
- Federal Grant Award Summary The National Cancer Institute awarded a $122,610 Project Grant to the University of Pennsylvania on August 11, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award, with a completion date of July 31, 2030, supports the development of a system to advance National Cancer Institute (NCI)-sponsored clinical trials for patients with rare gastrointestinal malignancies and rare disease populations. The project leverages the principal investigator's...